SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy

Breast Cancer Research and Treatment

Volumn 132, Issue 3, 2012, Pages 807-818

  Collie Duguid, Elaina S R ^a   Sweeney, Kathleen ^a   Stewart, Keith N ^a   Miller, Iain D ^b   Smyth, Elizabeth ^b   Heys, Steven D ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Breast cancer; Chemotherapy; Docetaxel; Predictive biomarker; Prognostic biomarker; SerpinB3

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; HEAT SHOCK PROTEIN 70; PREDNISOLONE; SERPINB3; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA RELATED ANTIGEN; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TAXOID; TUMOR ANTIGEN;

ACCURACY; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR MODEL; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TUMOR BIOPSY; ADJUVANT THERAPY; BREAST TUMOR; KAPLAN MEIER METHOD; LUNG CARCINOMA; METABOLISM; MINIMAL RESIDUAL DISEASE; MORTALITY; PAGET NIPPLE DISEASE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTHRACYCLINES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERPINS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84865169407     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1625-9     Document Type: Article

References (61)

1. Fisher ER, Wang JP, Bryant J, Fisher B, Mamounas E, Wolmark (2002) Pathobiology of preoperative chemotherapy-findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-18. Cancer 95:681-695
2. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785
3. van der Hage JA, van de Velde CJH, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L, Cooperating Investigators (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224-4237
4. Mauri D, Pavlidis N, Ioannidis JPA (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Nat Cancer Inst 97:188-194
5. Trudeau M, Sinclair SE, Clemons M (2005) Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review. Cancer Treat Rev 31:283-302
6. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26:814-819
7. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12:320-327
8. Hutcheon AW, Heys SD, Miller ID, Payne S, Smith IC, Ogston KN, Eremin OF, Sarkar TK (2001) Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: a randomised controlled trial. Breast Cancer Res Treat 69:298
9. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466
10. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 21:4165-4174
11. Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC, Ahrendt GM (2010) Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. Cancer 116:1431-1439
12. Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-De More N, Halle J, Sawyer L, Moore DT, Graham ML (2005) American joint committee on cancer tumor-nodemetastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Nat Cancer Inst 97:1137-1142
13. Chaturvedi S, McLaren C, Schofield A, Ogston KN, Sarkar TK, Hutcheon AW, Miller ID, Heys SD (2005) Patterns of local and distant disease relapse in patients with breast cancer treated with primary chemotherapy: do patients with a complete pathological response differ from those with residual tumour in the breast? Breast Cancer Res Treat 93:151-158
14. Heys SD, Sarkar T, Hutcheon AW (2005) Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival. Breast Cancer Res Treat 90:169-185
15. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124:133-140
16. von Minckwitz G, Untch M, Nuesch E, Loibl S, Kaufmann M, Kümmel S et al (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145-156
17. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A et al (2010) Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol (Epub ahead of print). http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2009. 27.5644
18. Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, Vrancken Peeters MJ, van Tinteren H, Van't Veer LJ, Rodenhuis S (2010) The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 119:551-558
19. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA et al (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-4244
20. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685
21. Dressman HK, Hans C, Bild A, Olson JA, Rosen E, Marcom PK et al (2006) Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 12:819-826
22. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M (2007) Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 8:1071-1078
23. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O, Heys SD, Gilbert FJ, Sharp PF (2000) Positron emission tomography using [F-18]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688
24. Rakha EA, El Rehim DA, Paish C, Green AR, Lee AH, Robertson JF, Blamey RW, Macmillan D, Ellis IO (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42:3149-3156
25. McIntosh SA, Ogston KN, Payne S, Miller ID, Sarkar TK, Hutcheon AW, Heys SD (2003) Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy. Am J Surg 185:525-531
26. Jaattela M (2004) Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 23:2746-2756
27. Leist M, Jaattela M (2001) Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2:589-598
28. Foghsgaard L, Wissing D, Mauch D, Lademann U, Bastholm L, Boes M, Elling F, Leist M, Jäätteläa M (2001) Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol 153:999-1009
29. Fehrenbacher N, Gyrd-Hansen M, Poulsen B, Felbor U, Kallunki T, Boes M, Weber E, Leist M, Jäättelä M (2004) Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res 64:5301-5310
30. Fehrenbacher N, Bastholm L, Kirkegaard-Sorensen T, Rafn B, Bøttzauw T, Nielsen C, Weber E, Shirasawa S, Kallunki T, Jäättelä M (2008) Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer Res 68:6623-6633
31. Groth-Pedersen L, Ostenfeld MS, Hoyer-Hansen M, Nylandsted J, Jäättelä M (2007) Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res 67:2217-2225
32. Broker LE, Huisman C, Span SW, Rodriguez JA, Kruyt FAE, Giaccone G (2004) Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res 64:27-30
33. Nylandsted J, Gyrd-Hansen M, Danielewicz A, Fehrenbacher N, Lademann U, Høyer-Hansen M, Weber E, Multhoff G, Rohde M, Jäättelä M (2004) Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med 200:425-435
34. Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J, Jäättelä M (2005) Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev 19:570-582
35. Nylandsted J, Rohde M, Brand K, Bastholm L, Elling F, Jäättelä M (2000) Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc Nat Acad Sci USA 97:7871-7876
36. Nylandsted J, Brand K, Jaattela M (2000) Heat shock protein 70 is required for the survival of cancer cells. Ann NY Acad Sci 926:122-125
37. Murakami A, Suminami Y, Hirakawa H, Nawata S, Numa F, Kato H (2001) Squamous cell carcinoma antigen suppresses radiation-induced cell death. Br J Cancer 84:851-858
38. Suminami Y, Nagashima S, Vujanovic NL, Hirabayashi K, Kato H, Whiteside TL (2000) Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1. Br J Cancer 82:981-989
39. Suminami Y, Nagashima S, Murakami A, Nawata S, Gondo T, Hirakawa H, Numa F, Silverman GA, Kato H et al (2001) Suppression of a squamous cell carcinoma (SCC)-related serpin, SCC antigen, inhibits tumor growth with increased intratumor infiltration of natural killer cells. Cancer Res 61:1776-1780
40. Petty RD, Kerr KM, Murray GI, Nicolson MC, Rooney PH, Bissett D, Collie-Duguid ESR (2006) Tumor transcriptome reveals the predictive and prognostic impactoflysosomal protease inhibitors in non-small-cell lung cancer. J Clin Oncol 2:1729-1744
41. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K (1982) A prognostic index in primary breast-cancer. Br J Cancer 45:361-366
42. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP et al (1987) Confirmation of a prognostic index in primary breast-cancer. Br J Cancer 56:489-492
43. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham prognostic index in primary breast-cancer. Breast Cancer Res Treat 22:207-219
44. Alonzo TA (2005) Standards for reporting prognostic tumor marker studies. J Clin Oncol 23:9053-9054
45. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 100:229-235
46. Rakha EA, El Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, Lee AH, Ellis IO (2008) Invasive lobular carcinomaofthebreast: response to hormonal therapy and outcomes. Eur J Cancer 44:73-83
47. Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M (2006) Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess 10:34
48. Chollet P, Amat S, Belembaogo E, Curé H, de Latour M, Dauplat J, Le Bouëdec G, Mouret-Reynier MA, Ferrière JP, Penault-Llorca F (2003) Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? Br J Cancer 89:1185-1191
49. Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA, Robertson JF, Mitchell MJ, Ball GR, Haybittle JL, Elston CW (2007) Survival of invasive breast cancer according to the Nottingham prognostic index in cases diagnosed in 1990-1999. Eur J Cancer 43:1548-1555
50. Nowak AK, Wilcken NRC, Stockler MR, Hamilton A, Ghersi D (2004) Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 5:372-380
51. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983
52. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23:3686-3696
53. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK (2007) Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 4: ARTN CD004421
54. Ellis P, Barrett P, Johnson L, Cameron D, Wardley A, O'Reilly S et al (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 373:1681-1692
55. Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN (2004) The use of alternate, noncross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 22:2294-2302
56. Campbell HE, Taylor MA, Harris AL, Gray AM (2009) An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer 101:1074-1084
57. Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD (2010) PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res 12:R1
58. ABS (2003) An audit of screen detected breast cancers for the year of screening April 2001 to March 2002. NHS Breast Screening Programme and Association of Breast Surgery at BASO. http://www.cancerscreening.nhs.uk/ breastscreen/publications/ba01-02.html. Accessed 1 Feb. 2011
59. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
60. Cardoso F, Piccart-Gebhart M, van't Veer L, Rutgers E, TRANSBIG Consortium (2007) The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol Oncol 1:246-251
61. Kim C, Paik S (2010) Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol 7:340-347